Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P146007
- Development stage
- Preclinical
- Lead developer
- West China Hospital of Sichuan University
01
Overview
P146007 is a lytic bacteriophage belonging to the genus *Slopekvirus* that targets carbapenem-resistant *Klebsiella pneumoniae* (CRKP) [01400]. Isolated from hospital sewage by researchers at West China Hospital of Sichuan University, P146007 exhibits a broad host range, infecting multiple ST11 subtypes of *K. pneumoniae* (including KL21, KL25, KL39, KL62, and KL64) [01400]. It targets the lipopolysaccharide (LPS) synthesis pathway of the host bacteria, with resistance to the phage linked to mutations in the *waa* gene cluster [01400]. P146007 has demonstrated synergistic in vitro antibacterial activity when combined with the narrow-host-range phage P066121, significantly extending the bacterial inhibition period against ST11-KL64 CRKP [01400].
- Other names
- Klebsiella phage P146007
Beyond the preview
Go deeper on P146007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P146007.